TY - JOUR
T1 - In vivo hypoxia-induced neuronal damage in dentate gyrus of rat hippocampus
T2 - Changes in NMDA receptors and the effect of MK-801
AU - Matsuoka, Yasuji
AU - Kitamura, Yoshihisa
AU - Fukunaga, Reiko
AU - Shimohama, Shun
AU - Nabeshima, Toshitaka
AU - Tooyama, Ikuo
AU - Kimura, Hiroshi
AU - Taniguchi, Takashi
N1 - Funding Information:
We would like to thank Ms C. Shimono and Mr M. Sakata for their technical assistance. This paper was supported in part by Grants-in-Aid (05670110; 06670128; 07670123; 08877024) for General Scientific Research from the Ministry of Education, Science, Sports and Culture, Japan (T.T.), and by a Grant-in-Aid (08772121) for the Encouragement of Young Scientists from the Ministry of Education, Science, Sports and Culture, Japan (Y.K.).
PY - 1997/6/7
Y1 - 1997/6/7
N2 - Hypoxia is a major cause of ischaemia-induced neuronal damage. In the present study, we examined the effects of in vivo hypoxia on N-methyl-D-aspartate receptors (NMDAR) in the rat hippocampus. This model of in vivo hypoxia involved placing rats in a hypoxic chamber containing 5% O2 and 95% N2 for 30 min. In the hippocampus, neuronal cells in the CA3, the hilus of the dentate gyrus and the dentate gyrus (DG) were damaged. In the CA1, which is known to be vulnerable to ischaemic damage, neuronal cells did not show hypoxia-induced damage. In vivo hypoxia-induced damage caused morphological changes in neuronal cells, such as shrunken, spindle or triangular shapes accompanied by pyknotic nuclei, but did not induce the loss of neuronal cells. On the other hand, the number of binding sites for [3H]-1-[1-(2-thienyl)cyclohexyl]-3,4-piperidine hydrochloride (TCP) gradually decreased on and after 7 days, and then maximally decreased by 25% at 21 days after hypoxia. The number of NMDAR1-immunopositive cells was decreased by 22% in the DG, but was unchanged in the CA3. Furthermore, we examined the effect of a non-competitive NMDA antagonist, (+)-5-methyl-10:11-dihydro-5H-dibenzo[a,b] cyclohepten-5,10-imine hydrogen maleate (MK-801), on against in vivo hypoxia. The administration of MK-801 (3 mg/kg, i.p.), 30 min before hypoxia treatment, partly protected against neuronal damage in the DG, but not in the CA3. These results suggest that hypoxia-induced neuronal damage in the DG involves, in part, the activation of NMDAR.
AB - Hypoxia is a major cause of ischaemia-induced neuronal damage. In the present study, we examined the effects of in vivo hypoxia on N-methyl-D-aspartate receptors (NMDAR) in the rat hippocampus. This model of in vivo hypoxia involved placing rats in a hypoxic chamber containing 5% O2 and 95% N2 for 30 min. In the hippocampus, neuronal cells in the CA3, the hilus of the dentate gyrus and the dentate gyrus (DG) were damaged. In the CA1, which is known to be vulnerable to ischaemic damage, neuronal cells did not show hypoxia-induced damage. In vivo hypoxia-induced damage caused morphological changes in neuronal cells, such as shrunken, spindle or triangular shapes accompanied by pyknotic nuclei, but did not induce the loss of neuronal cells. On the other hand, the number of binding sites for [3H]-1-[1-(2-thienyl)cyclohexyl]-3,4-piperidine hydrochloride (TCP) gradually decreased on and after 7 days, and then maximally decreased by 25% at 21 days after hypoxia. The number of NMDAR1-immunopositive cells was decreased by 22% in the DG, but was unchanged in the CA3. Furthermore, we examined the effect of a non-competitive NMDA antagonist, (+)-5-methyl-10:11-dihydro-5H-dibenzo[a,b] cyclohepten-5,10-imine hydrogen maleate (MK-801), on against in vivo hypoxia. The administration of MK-801 (3 mg/kg, i.p.), 30 min before hypoxia treatment, partly protected against neuronal damage in the DG, but not in the CA3. These results suggest that hypoxia-induced neuronal damage in the DG involves, in part, the activation of NMDAR.
UR - http://www.scopus.com/inward/record.url?scp=0030980091&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030980091&partnerID=8YFLogxK
U2 - 10.1016/S0197-0186(96)00125-8
DO - 10.1016/S0197-0186(96)00125-8
M3 - Article
C2 - 9152994
AN - SCOPUS:0030980091
SN - 0197-0186
VL - 30
SP - 533
EP - 542
JO - Neurochemistry International
JF - Neurochemistry International
IS - 6
ER -